亚盛医药-B(06855.HK)发布中期业绩 收益2.34亿元 耐立克（奥雷巴替尼）在中国的产品销售同比大幅增长93%

Group 1 - The company achieved revenue of RMB 234 million for the six months ending June 30, 2025 [1] - Sales of Nairik® (Orebatebine) in China increased by RMB 105 million or 93% to RMB 217 million in the first half of 2025, compared to RMB 113 million for the six months ending June 30, 2024 [1]